Bayoquitin

Bayoquitin is an oral atypical antipsychotic developed and marketed by the Iranian pharmaceutical company Bakhtar Bioshimi. It is a generic formulation of quetiapine, a dibenzothiazepine derivative. The drug functions as an antagonist at multiple neurotransmitter receptors, with its primary therapeutic effects mediated through antagonism of the serotonin 5-HT2A and dopamine D2 receptors. It also exhibits high affinity for histamine H1 and adrenergic alpha-1 receptors, which contributes to its sedative properties. Bayoquitin is indicated for the treatment of schizophrenia and various manifestations of bipolar disorder, including acute manic episodes and bipolar depression.

Brand names

Bayoquitin

Other names

بایوکویتین